ADVENZYMES302.20

Advanced Enzyme Tech Ltd.

· Pharma & Health
₹ CrorePeersAARTIPHARMAARTIDRUGSAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹3,382 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity9.728.9310.0210.02
Return on Assets8.928.269.449.44
Return on Capital Employed11.8410.3610.9110.91
Return on Invested Capital14.0312.3313.9513.47
Margins
EBITDA Margin32.7730.5330.7229.83
Operating Margin27.1224.7925.3425.34
Incremental Operating Margin-86.9328.57
Pretax Margin30.1129.4231.1830.84
Net Income Margin21.9521.0323.2822.91
Net Income to Common Margin21.3720.5922.6222.13
FCF Margin15.8716.9114.0014.00
Additional
Effective Tax Rate27.0828.5025.3425.70
Dvd Payout Ratio41.4144.0634.43
Sustainable Growth Rate5.695.006.5710.02
Incremental Operating Margin %-86.9328.57-147.85
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.